These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 18577158

  • 1. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
    Levin P.
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries.
    Gschwend MH, Aagren M, Valentine WJ.
    J Med Econ; 2009 Jun; 12(2):114-23. PubMed ID: 19545216
    [Abstract] [Full Text] [Related]

  • 3. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden.
    Valentine WJ, Aagren M, Haglund M, Ericsson A, Gschwend MH.
    Scand J Public Health; 2011 Feb; 39(1):79-87. PubMed ID: 20688795
    [Abstract] [Full Text] [Related]

  • 5. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O, Breitscheidel L, Benter U, Dippel FW, Müller M, Volk M, Pfohl M.
    J Med Econ; 2008 Feb; 11(4):695-712. PubMed ID: 19450076
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ.
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [Abstract] [Full Text] [Related]

  • 7. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.
    Lee LJ, Yu AP, Johnson SJ, Birnbaum HG, Atanasov P, Buesching DP, Jackson JA, Davidson JA.
    Diabetes Res Clin Pract; 2010 Jan; 87(1):108-16. PubMed ID: 19896233
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.
    Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G.
    Diabetes Obes Metab; 2009 Nov; 11(11):1068-79. PubMed ID: 19732121
    [Abstract] [Full Text] [Related]

  • 9. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
    Ali M, White J, Lee CH, Palmer JL, Smith-Palmer J, Fakhoury W, Valentine WJ.
    J Med Econ; 2008 Nov; 11(4):651-70. PubMed ID: 19450074
    [Abstract] [Full Text] [Related]

  • 10. [Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark].
    Palmer AJ, Lammert M, Hermansen K.
    Ugeskr Laeger; 2008 Apr 07; 170(15):1250-4. PubMed ID: 18433583
    [Abstract] [Full Text] [Related]

  • 11. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes.
    Dailey G, Strange P.
    Am J Manag Care; 2008 Jan 07; 14(1):25-30. PubMed ID: 18197742
    [Abstract] [Full Text] [Related]

  • 12. Technology and the issue of cost/benefit in diabetes.
    Giannini C, Mohn A, Chiarelli F.
    Diabetes Metab Res Rev; 2009 Sep 07; 25 Suppl 1():S34-44. PubMed ID: 19662616
    [Abstract] [Full Text] [Related]

  • 13. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
    Gupta V, Baabbad R, Hammerby E, Nikolajsen A, Shafie AA.
    J Med Econ; 2015 Apr 07; 18(4):263-72. PubMed ID: 25426701
    [Abstract] [Full Text] [Related]

  • 14. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
    Permsuwan U, Chaiyakunapruk N, Dilokthornsakul P, Thavorn K, Saokaew S.
    Appl Health Econ Health Policy; 2016 Jun 07; 14(3):281-92. PubMed ID: 26961276
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
    Ridderstråle M, Jensen MM, Gjesing RP, Niskanen L.
    J Med Econ; 2013 Jun 07; 16(4):468-78. PubMed ID: 23384160
    [Abstract] [Full Text] [Related]

  • 16. Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial.
    Janka HU, Högy B.
    Eur J Health Econ; 2008 May 07; 9(2):165-70. PubMed ID: 17530309
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of insulin analogs.
    Brixner DI, McAdam-Marx C.
    Am J Manag Care; 2008 Nov 07; 14(11):766-75. PubMed ID: 18999911
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
    Lee KH, Seo SJ, Smith-Palmer J, Palmer JL, White J, Valentine WJ.
    Value Health; 2009 Nov 07; 12 Suppl 3():S55-61. PubMed ID: 20586983
    [Abstract] [Full Text] [Related]

  • 19. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany.
    Pfohl M, Schädlich PK, Dippel FW, Koltermann KC.
    J Med Econ; 2012 Nov 07; 15 Suppl 2():14-27. PubMed ID: 22812690
    [Abstract] [Full Text] [Related]

  • 20. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
    De Mattia G, Laurenti O, Moretti A.
    Acta Diabetol; 2009 Mar 07; 46(1):67-73. PubMed ID: 19030772
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.